Skip to Main Content

E3303/SCCC 2005009: Phase II Study of C225 (Erbitux or Cetuximab) In Combination with Cisplatin and Definitive Radiation in Unresectable Stage 4 Squamos Cell Carcinoma of the Head and Neck

Principal Investigator

Khaled Tolba

Clinical Trial ID

Institutional Protocol # 20101068

Clinical Trial Summary


Phase

Phase II


Funding Agency/Sponsor

National Cooperative Group


Disease

Head and Neck Cancer



Contact Information

Phone Number 305-243-2647